Let’s start working together, today. You can contact us!
NBLST
Latest Updates
January 30, 2026
In-depth Analysis of PD-L1 Target: Why It Has Become a "Star Target" in Cancer Immunotherapy?
In the golden track of cancer immunotherapy, immunotherapy targeting PD-1 (Programmed Death Receptor 1) has become a classic paradigm, but its single-target strategy faces bottlenecks in clinical...
January 30, 2026
January 23, 2026
Dual-Action Strategy: Novel Bispecific Nanobodies Achieve Dual Defense through Virus "Neutralization" and "Physical Trapping"
Despite advances in vaccines and antiviral drugs, the prevention and transmission of respiratory viral infections remain major global challenges. A significant limitation of existing approaches is...
January 23, 2026
January 16, 2026
A New Hope for Bradycardia? Nanobody Agonist NB5 Successfully Increases Pacing Frequency in Human-Derived Cardiomyocytes
A recent report in Nature Communications highlights a significant breakthrough: researchers have successfully developed a nanobody named NB5 capable of precisely "remotely controlling" the heart's...
January 16, 2026
Support is Online
We're back! We are here to assist you. Please be patient, we will respond to your tickets shortly.
Official support hours
Monday To Friday
From 9:00AM To 6:00PM
Address
Building A, 15th Floor, WHIIID Headquarters, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, P.R of China
Call Us now
Email & Social